{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(5)"],"submitter":["Lee CK"],"funding":["Janssen Korea Ltd"],"pubmed_abstract":["<h4>Background</h4>This study investigated the safety and effectiveness of ustekinumab (UST) in Korean patients with Crohn's disease (CD).<h4>Methods</h4>Adult patients with CD treated with UST were prospectively enrolled in the K-STAR (Post-MarKeting Surveillance for Crohn's Disease patients treated with STelARa) study between April 2018 and April 2022. Both the clinical effectiveness and adverse effects of UST therapy were analyzed. Missing data were handled using nonresponder imputation (ClinicalTrials.gov Identifier: NCT03942120).<h4>Results</h4>Of the 464 patients enrolled from 44 hospitals across Korea, 457 and 428 patients (Crohn's disease activity index ≥150) were included in the safety analysis and effectiveness analysis sets, respectively. At weeks 16 to 20 after initiating UST, "],"journal":["Inflammatory bowel diseases"],"pagination":["1306-1316"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12069984"],"repository":["biostudies-literature"],"pubmed_title":["One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study."],"pmcid":["PMC12069984"],"pubmed_authors":["Choi JM","Ye BD","Choi CH","Kim HS","Song GA","Kim ES","Lee YJ","Moon W","Chun J","Lee CK","Yoon H","Jung SY","Kim HW","Park SC","Jung Y","Kim Y","Jung ES","Lee JH"],"additional_accession":[]},"is_claimable":false,"name":"One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study.","description":"<h4>Background</h4>This study investigated the safety and effectiveness of ustekinumab (UST) in Korean patients with Crohn's disease (CD).<h4>Methods</h4>Adult patients with CD treated with UST were prospectively enrolled in the K-STAR (Post-MarKeting Surveillance for Crohn's Disease patients treated with STelARa) study between April 2018 and April 2022. Both the clinical effectiveness and adverse effects of UST therapy were analyzed. Missing data were handled using nonresponder imputation (ClinicalTrials.gov Identifier: NCT03942120).<h4>Results</h4>Of the 464 patients enrolled from 44 hospitals across Korea, 457 and 428 patients (Crohn's disease activity index ≥150) were included in the safety analysis and effectiveness analysis sets, respectively. At weeks 16 to 20 after initiating UST, ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-02T17:56:48.751Z","creation":"2026-04-18T03:11:58.375Z"},"accession":"S-EPMC12069984","cross_references":{"pubmed":["39096895"],"doi":["10.1093/ibd/izae171"]}}